Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:pyridinecarboxamide
go back to main search page
Accession:CHEBI:25529 term browser browse the term
Definition:A member of the class of pyridines that is a substituted pyridine in which at least one of the substituents is a carboxamide or N-substituted caraboxamide group.
Synonyms:related_synonym: pyridinecarboxamides



show annotations for term's descendants           Sort by:
 
1-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
G Dek DEK proto-oncogene decreases chemical synthesis ISO DEK protein results in decreased chemical synthesis of N(1)-methylnicotinamide CTD PMID:28558019 NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
JBrowse link
G Lepr leptin receptor affects abundance ISO LEPR affects the abundance of N(1)-methylnicotinamide CTD PMID:20567778 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA] CTD PMID:32298659 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression EXP N(1)-methylnicotinamide results in increased expression of PTGS2 mRNA CTD PMID:18385449 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Retn resistin multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of RETN mRNA] CTD PMID:32298659 NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
JBrowse link
G Slc22a1 solute carrier family 22 member 1 increases import ISO SLC22A1 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
JBrowse link
G Slc22a16 solute carrier family 22 member 16 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] CTD PMID:15963465 NCBI chr20:43,972,808...44,068,447 JBrowse link
G Slc22a2 solute carrier family 22 member 2 increases import ISO SLC22A2 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Slc22a3 solute carrier family 22 member 3 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] CTD PMID:10966924 NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
JBrowse link
CGP-42112A term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions ISO CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 protein]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]; CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]; CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]] CTD PMID:25446015 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Agtr2 angiotensin II receptor, type 2 multiple interactions ISO
EXP
CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]; CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]]
[CGP 42112A binds to and results in increased activity of AGTR2 protein] which affects the susceptibility to Phenylephrine; [CGP 42112A binds to and results in increased activity of AGTR2 protein] which results in increased abundance of and results in increased secretion of Triglycerides; [CGP 42112A binds to and results in increased activity of AGTR2 protein] which results in increased abundance of Fatty Acids, Nonesterified; CGP 42112A binds to and results in increased activity of AGTR2 protein
CTD PMID:16003179 PMID:19151255 PMID:25446015 NCBI chr  X:112,119,673...112,124,060
Ensembl chr  X:112,120,228...112,124,057
JBrowse link
G Agtrap angiotensin II receptor-associated protein multiple interactions ISO CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]] CTD PMID:25446015 NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036
JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]] CTD PMID:25446015 NCBI chr  X:13,360,583...13,392,517
Ensembl chr  X:13,359,430...13,392,586
JBrowse link
G Nox1 NADPH oxidase 1 multiple interactions ISO CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]] CTD PMID:25446015 NCBI chr  X:97,279,058...97,332,291
Ensembl chr  X:97,279,056...97,302,236
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions ISO CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]] CTD PMID:25446015 NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
JBrowse link
G Ube2v2 ubiquitin conjugating enzyme E2 V2 increases expression EXP CGP 42112A results in increased expression of UBE2V2 mRNA; CGP 42112A results in increased expression of UBE2V2 protein CTD PMID:17068200 NCBI chr11:85,304,528...85,338,430
Ensembl chr11:85,304,526...85,336,369
JBrowse link
isonicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bglap bone gamma-carboxyglutamate protein increases expression EXP
ISO
isonicotinamide results in increased expression of BGLAP mRNA CTD PMID:16813520 PMID:21745208 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Fabp4 fatty acid binding protein 4 decreases expression
increases expression
ISO isonicotinamide results in decreased expression of FABP4 mRNA
isonicotinamide results in increased expression of FABP4 mRNA
CTD PMID:16813520 NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases expression ISO isonicotinamide results in decreased expression of PPARG mRNA CTD PMID:16813520 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Runx2 RUNX family transcription factor 2 increases expression ISO isonicotinamide results in increased expression of RUNX2 mRNA CTD PMID:21745208 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Sirt1 sirtuin 1 increases activity
increases expression
ISO isonicotinamide results in increased activity of SIRT1 protein
isonicotinamide results in increased expression of SIRT1 mRNA
CTD PMID:21745208 NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Sp7 Sp7 transcription factor increases expression ISO isonicotinamide results in increased expression of SP7 mRNA CTD PMID:21745208 NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
JBrowse link
G Spp1 secreted phosphoprotein 1 increases expression ISO isonicotinamide results in increased expression of SPP1 mRNA CTD PMID:21745208 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B increases expression ISO isonicotinamide results in increased expression of TNFRSF11B mRNA CTD PMID:16813520 NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
JBrowse link
N-methyl-6-pyridone-3-carboxamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Lepr leptin receptor affects abundance ISO LEPR affects the abundance of N'-methyl-2-pyridone-5-carboxamide CTD PMID:20567778 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
JBrowse link
N-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of N-methylnicotinamide
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of N-methylnicotinamide]
CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of N-methylnicotinamide CTD PMID:21561886 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
JBrowse link
N-ribosylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions ISO nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]; nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions
increases oxidation
ISO [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of 2,6-Dichloroindophenol; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q1; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]
NQO2 protein results in increased oxidation of nicotinamide-beta-riboside; NQO2 protein results in increased oxidation of nicotinamide-beta-riboside metabolite
CTD PMID:20399199 PMID:29281794 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
JBrowse link
nicorandil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc9 ATP binding cassette subfamily C member 9 increases activity ISO Nicorandil results in increased activity of ABCC9 protein CTD PMID:22622455 NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
JBrowse link
G Agt angiotensinogen multiple interactions ISO Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] CTD PMID:22622455 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of BAX protein] CTD PMID:31376360 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] CTD PMID:31376360 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Cat catalase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of CAT protein] CTD PMID:31376360 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ctsd cathepsin D multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] CTD PMID:11829124 PMID:14499179 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
JBrowse link
G Gal galanin and GMAP prepropeptide multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GAL protein] CTD PMID:11829124 PMID:14499179 NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
JBrowse link
G Gusb glucuronidase, beta multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] CTD PMID:11829124 PMID:14499179 NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:31376360 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
JBrowse link
G Hmox1 heme oxygenase 1 decreases expression EXP Nicorandil results in decreased expression of HMOX1 protein CTD PMID:22622455 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] CTD PMID:31376360 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of MPO protein] CTD PMID:31376360 NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein] CTD PMID:31376360 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of NFKB1 protein] CTD PMID:31376360 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP Nicorandil results in increased expression of SOD2 protein CTD PMID:22622455 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TLR4 protein] CTD PMID:31376360 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TNF protein] CTD PMID:31376360 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Xdh xanthine dehydrogenase multiple interactions
decreases expression
ISO
EXP
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein]
Nicorandil results in decreased expression of XDH protein
CTD PMID:22622455 NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
JBrowse link
nicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha multiple interactions
decreases phosphorylation
ISO
EXP
Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein]
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]
Niacinamide results in decreased phosphorylation of ACACA protein
CTD PMID:18482975 PMID:19071085 PMID:21212096 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases secretion
multiple interactions
ISO
EXP
Niacinamide results in increased secretion of ADIPOQ protein
[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein]
CTD PMID:17452443 PMID:21439372 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Ago2 argonaute RISC catalytic component 2 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein] CTD PMID:24792773 NCBI chr 7:105,018,202...105,105,120
Ensembl chr 7:105,029,120...105,104,974
JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions EXP [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA CTD PMID:18420994 NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein] CTD PMID:25478867 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
EXP
ISO
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of BAX protein]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX mRNA]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX protein]
[Berberine co-treated with Niacinamide] results in increased expression of BAX protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]
Niacinamide results in increased expression of BAX mRNA; Niacinamide results in increased expression of BAX protein
CTD PMID:16168987 PMID:16998810 PMID:22164206 PMID:25478867 PMID:26712469 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA
Niacinamide results in increased expression of BBC3 mRNA
CTD PMID:26712469 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]
CTD PMID:25472572 PMID:25478867 PMID:26712469 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein]
Niacinamide results in increased expression of BCL2L11 mRNA
CTD PMID:25472572 PMID:26712469 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Bmi1 BMI1 proto-oncogene, polycomb ring finger multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein] CTD PMID:24792773 NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased activity of CASP3 protein]
Niacinamide results in increased cleavage of CASP3 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; resveratrol inhibits the reaction [Niacinamide results in increased cleavage of CASP3 protein]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
CTD PMID:16505238 PMID:22164206 PMID:24040102 PMID:24962570 PMID:25478867 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]
CTD PMID:16505238 PMID:25478867 PMID:26712469 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cat catalase multiple interactions EXP [Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Saponins inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein] CTD PMID:20307516 PMID:21382363 PMID:21439372 PMID:21630391 PMID:22056647 More... NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Niacinamide results in decreased expression of CCL2 protein CTD PMID:14627904 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 increases expression ISO Niacinamide results in increased expression of CCL20 mRNA CTD PMID:22385246 NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
JBrowse link
G Cd40 CD40 molecule multiple interactions ISO Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA] CTD PMID:22717288 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
decreases expression
ISO
EXP
Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein]
Niacinamide results in increased expression of CDKN1A protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]
Niacinamide results in decreased expression of CDKN1A protein
CTD PMID:12782109 PMID:22561310 PMID:25478867 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression
multiple interactions
EXP Niacinamide results in increased expression of CDKN1B protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
CTD PMID:22561310 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter] CTD PMID:24792773 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases activity
multiple interactions
ISO Niacinamide results in increased activity of CHUK protein
resveratrol inhibits the reaction [Niacinamide results in increased activity of CHUK protein]
CTD PMID:24962570 NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of COL1A1 mRNA
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]
CTD PMID:16813520 PMID:25707573 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions
increases expression
EXP Clofibrate inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]; GW 6471 inhibits the reaction [Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]]; Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA] CTD PMID:23422569 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA] CTD PMID:27919644 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA] CTD PMID:27919644 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Defb4 defensin beta 4 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA CTD PMID:24894820 NCBI chr16:70,650,472...70,653,665
Ensembl chr16:70,650,472...70,653,665
JBrowse link
G Dicer1 dicer 1 ribonuclease III multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein] CTD PMID:24792773 NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965
JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA] CTD PMID:21232033 NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein] CTD PMID:24792773 NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of EIF4EBP1 protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Niacinamide inhibits the reaction [Resveratrol results in decreased phosphorylation of EIF4EBP1 protein]
CTD PMID:19928762 PMID:20169165 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor increases abundance
multiple interactions
ISO ERCC6 gene mutant form results in increased abundance of Niacinamide
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased abundance of Niacinamide]
CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G F3 coagulation factor III, tissue factor decreases expression ISO Niacinamide results in decreased expression of F3 protein CTD PMID:14627904 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of FOS protein] CTD PMID:16168987 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO
EXP
Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC mRNA]; Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Niacinamide results in increased expression of and results in increased acetylation of FOXO1 protein
Niacinamide inhibits the reaction [Dexamethasone results in decreased acetylation of FOXO1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]
CTD PMID:16917544 PMID:20181797 PMID:26712469 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of and results in increased expression of FOXO3 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of FOXO3 protein]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of FOXO3 protein]; Niacinamide results in increased expression of and results in increased acetylation of FOXO3 protein CTD PMID:23022493 PMID:25472572 PMID:26712469 NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC mRNA] CTD PMID:16917544 NCBI chr10:86,307,400...86,318,766 JBrowse link
G G6pd glucose-6-phosphate dehydrogenase multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein] CTD PMID:19059388 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801
JBrowse link
G Gcg glucagon multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA; Sitagliptin Phosphate inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA] CTD PMID:23466488 NCBI chr 3:47,113,914...47,122,929
Ensembl chr 3:47,113,914...47,122,929
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein] CTD PMID:21439372 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions
increases expression
EXP Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Niacinamide results in increased expression of GLB1 protein
CTD PMID:22561310 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
JBrowse link
G Glo1 glyoxalase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein] CTD PMID:21439372 NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP [Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of GPT protein] CTD PMID:32894639 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP [Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in decreased expression of GSR protein]; [Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein] CTD PMID:20307516 PMID:21439372 PMID:32894639 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Gstm5 glutathione S-transferase, mu 5 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA] CTD PMID:21439372 NCBI chr 2:195,531,627...195,534,562
Ensembl chr 2:195,531,495...195,534,553
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions EXP [Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of GSTP1 protein] CTD PMID:32894639 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
G Gys2 glycogen synthase 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein] CTD PMID:19059388 NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228
JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein] CTD PMID:19647726 NCBI chr10:15,323,830...15,324,677 JBrowse link
G Hdac1 histone deacetylase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein] CTD PMID:24792773 NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions EXP [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein] CTD PMID:20696151 PMID:21212096 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein] CTD PMID:21439372 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] CTD PMID:24145604 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA CTD PMID:29594315 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA] CTD PMID:16917544 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
JBrowse link
G Il18 interleukin 18 multiple interactions EXP [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL18 mRNA CTD PMID:28322830 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein; [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL1B mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]
Niacinamide results in decreased expression of IL1B mRNA
Niacinamide results in increased expression of IL1B mRNA
CTD PMID:20307516 PMID:21439372 PMID:22385246 PMID:28322830 PMID:29594315 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il6 interleukin 6 decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of IL6 protein
[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]
CTD PMID:12727023 PMID:20307516 PMID:21439372 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Ins2 insulin 2 multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein] CTD PMID:16505238 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of JUN protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of JUN protein] CTD PMID:16168987 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein] CTD PMID:21439372 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
JBrowse link
G Klf4 Kruppel like factor 4 multiple interactions EXP [Streptozocin co-treated with Niacinamide] promotes the reaction [Dronabinol results in increased expression of KLF4 mRNA] CTD PMID:31081965 NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein] CTD PMID:20696151 NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972
JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein] CTD PMID:20696151 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
JBrowse link
G Mafa MAF bZIP transcription factor A multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]] CTD PMID:16505238 NCBI chr 7:107,432,292...107,435,061
Ensembl chr 7:107,433,605...107,434,690
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form] CTD PMID:24145604 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of MAPK8 protein] CTD PMID:16168987 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO Niacinamide results in increased expression of MDM2 mRNA CTD PMID:16998810 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
JBrowse link
G Mir3545 microRNA 3545 multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter] CTD PMID:24792773 NCBI chr 6:131,199,542...131,199,656
Ensembl chr 6:131,199,542...131,199,656
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression
multiple interactions
ISO Niacinamide results in increased expression of MMP9 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of MMP9 protein]
CTD PMID:24145604 PMID:24962570 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Msra methionine sulfoxide reductase A multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in increased expression of MSRA protein] CTD PMID:23022493 NCBI chr15:38,363,459...38,677,406
Ensembl chr15:38,351,445...38,676,585
JBrowse link
G Mtor mechanistic target of rapamycin kinase increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of MTOR protein
Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of MTOR protein]
CTD PMID:19928762 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in increased expression of and results in increased localization of MYC protein] CTD PMID:22028816 PMID:24792773 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nabp2 nucleic acid binding protein 2 decreases ubiquitination
increases acetylation
multiple interactions
ISO Niacinamide results in decreased ubiquitination of NABP2 protein
Niacinamide results in increased acetylation of NABP2 protein
Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein]
CTD PMID:26170237 NCBI chr 7:830,949...836,551
Ensembl chr 7:830,949...838,027
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of NAMPT protein
Niacinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA]
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein
CTD PMID:26712469 PMID:32298659 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
JBrowse link
G Ncor1 nuclear receptor co-repressor 1 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of NCOR1 protein
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]
CTD PMID:22539994 NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA1 mRNA] CTD PMID:23891692 NCBI chr  X:116,424,223...116,427,875
Ensembl chr  X:116,424,223...116,428,633
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 mRNA]; Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 protein] CTD PMID:23891692 NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
JBrowse link
G Ndufa2 NADH:ubiquinone oxidoreductase subunit A2 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA2 mRNA] CTD PMID:23891692 NCBI chr18:28,355,774...28,357,863
Ensembl chr18:28,355,774...28,358,076
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein] CTD PMID:21439372 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions EXP [Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of NFKB1 mRNA] CTD PMID:32894639 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 mRNA]; Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 protein] CTD PMID:23735732 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
increases expression
EXP GW 6471 inhibits the reaction [resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA] CTD PMID:23422569 NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions ISO [Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA CTD PMID:20505214 NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
JBrowse link
G Ogdh oxoglutarate dehydrogenase multiple interactions ISO Niacinamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of OGDH protein] CTD PMID:18381761 NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage
decreases activity
EXP
ISO
Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of PARP1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased cleavage of PARP1 protein]
Niacinamide results in increased expression of PARP1 mRNA; Niacinamide results in increased expression of PARP1 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein
Niacinamide results in increased cleavage of PARP1 protein
Niacinamide results in decreased activity of PARP1 protein
CTD PMID:16168987 PMID:19288225 PMID:22164206 PMID:26712469 PMID:29143419 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased expression of PDK4 protein] CTD PMID:20181797 NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
JBrowse link
G Pdp1 pyruvate dehydrogenase phosphatase catalytic subunit 1 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased phosphorylation of PDP1 protein] CTD PMID:20181797 NCBI chr 5:25,446,843...25,455,107
Ensembl chr 5:25,446,272...25,455,217
JBrowse link
G Pitx2 paired-like homeodomain 2 increases expression ISO Niacinamide results in increased expression of PITX2 mRNA; Niacinamide results in increased expression of PITX2 protein CTD PMID:29143419 NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293
JBrowse link
G Pmp22 peripheral myelin protein 22 multiple interactions ISO Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of and results in decreased localization of PMP22 protein] CTD PMID:22028816 NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
ISO Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein] CTD PMID:22539994 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases acetylation
multiple interactions
ISO
EXP
Niacinamide results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]
CTD PMID:19071085 PMID:23422569 PMID:23891692 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA1 protein] CTD PMID:18482975 NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
JBrowse link
G Prkaa2 protein kinase AMP-activated catalytic subunit alpha 2 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA2 protein] CTD PMID:18482975 NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Niacinamide results in increased expression of PTGS2 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PTGS2 protein]
CTD PMID:24145604 PMID:24962570 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Pygl glycogen phosphorylase L multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Metformin inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Salicylic Acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]
Niacinamide results in increased acetylation of and results in increased phosphorylation of RELA protein; resveratrol inhibits the reaction [Niacinamide results in increased phosphorylation of and results in increased acetylation of RELA protein]
Niacinamide inhibits the reaction [resveratrol results in decreased expression of RELA protein modified form]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]
CTD PMID:20307516 PMID:21439372 PMID:22717288 PMID:23406761 PMID:23735732 More... NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein CTD PMID:20169165 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression
multiple interactions
increases expression
ISO
EXP
Niacinamide results in decreased expression of RUNX2 mRNA; Niacinamide results in decreased expression of RUNX2 protein
resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]
Niacinamide results in increased expression of RUNX2 mRNA
CTD PMID:16813520 PMID:22539994 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions
increases expression
ISO Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein]
Niacinamide results in increased expression of SHC1 mRNA; Niacinamide results in increased expression of SHC1 protein
CTD PMID:21778425 PMID:24557422 NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
decreases activity
ISO
EXP
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol; Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA]
Niacinamide results in decreased expression of SIRT1 protein
[Niacinamide co-treated with Resveratrol] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Fructose; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Metformin; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Salicylic Acid; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA; [Resveratrol co-treated with Niacinamide] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of and results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 mRNA]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]
Niacinamide results in decreased expression of SIRT1 mRNA; Niacinamide results in decreased expression of SIRT1 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]
CTD PMID:16366736 PMID:17103016 PMID:18420994 PMID:18482975 PMID:18681908 More... NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Sirt2 sirtuin 2 decreases activity
multiple interactions
ISO Niacinamide results in decreased activity of SIRT2 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein
CTD PMID:17341628 PMID:26712469 NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
JBrowse link
G Sirt3 sirtuin 3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein CTD PMID:26712469 NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in decreased expression of SLC2A4 mRNA] CTD PMID:32298659 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of Niacinamide CTD PMID:21561886 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
JBrowse link
G Snap23 synaptosome associated protein 23 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA] CTD PMID:25999625 NCBI chr 3:107,514,088...107,546,177 JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein; Dronabinol promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein] CTD PMID:31081965 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA]
Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SOD2 protein]
CTD PMID:23891692 PMID:25472572 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Sox9 SRY-box transcription factor 9 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of SOX9 protein
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]; resveratrol inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]
CTD PMID:24962570 NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] CTD PMID:24238063 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]] CTD PMID:23319015 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Stx4 syntaxin 4 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA] CTD PMID:25999625 NCBI chr 1:182,451,108...182,459,701
Ensembl chr 1:182,451,117...182,459,979
JBrowse link
G Tgfb2 transforming growth factor, beta 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]
Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]
Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]; Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA]
Niacinamide results in increased expression of TNF mRNA
CTD PMID:20307516 PMID:21439372 PMID:22385246 PMID:22717288 PMID:24145604 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B decreases expression ISO Niacinamide results in decreased expression of TNFRSF11B mRNA CTD PMID:16813520 NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
JBrowse link
G Tnfsf11 TNF superfamily member 11 decreases expression ISO Niacinamide results in decreased expression of TNFSF11 mRNA CTD PMID:16813520 NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]; Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]
Niacinamide results in decreased expression of TP53 protein
CTD PMID:12782109 PMID:18482975 PMID:18681908 PMID:25478867 PMID:26712469 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Ucp2 uncoupling protein 2 multiple interactions ISO Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA] CTD PMID:16366736 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
JBrowse link
G Vamp2 vesicle-associated membrane protein 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA] CTD PMID:25999625 NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809
JBrowse link
regorafenib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atp5f1a ATP synthase F1 subunit alpha decreases expression EXP regorafenib results in decreased expression of ATP5F1A protein CTD PMID:33166663 NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
JBrowse link
G Casp3 caspase 3 increases cleavage
increases activity
ISO regorafenib results in increased cleavage of CASP3 protein
regorafenib results in increased activity of CASP3 protein
CTD PMID:29341879 PMID:30801954 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 increases activity ISO regorafenib results in increased activity of CASP8 protein CTD PMID:30801954 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Ccnd1 cyclin D1 decreases expression ISO regorafenib results in decreased expression of CCND1 protein CTD PMID:30801954 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing
affects metabolic processing
ISO CYP3A4 protein results in increased metabolism of regorafenib
CYP3A4 polymorphism affects the metabolism of regorafenib
CTD PMID:31293154 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Dnm1l dynamin 1-like increases expression EXP regorafenib results in increased expression of DNM1L mRNA CTD PMID:33166663 NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
JBrowse link
G Fas Fas cell surface death receptor increases activity ISO regorafenib results in increased activity of FAS protein CTD PMID:30801954 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
JBrowse link
G Faslg Fas ligand increases activity ISO regorafenib results in increased activity of FASLG protein CTD PMID:30801954 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fis1 fission, mitochondrial 1 increases expression EXP regorafenib results in increased expression of FIS1 mRNA CTD PMID:33166663 NCBI chr12:19,708,558...19,723,392
Ensembl chr12:19,708,558...19,723,377
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO regorafenib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation ISO regorafenib results in decreased phosphorylation of MAPK1 protein CTD PMID:30801954 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation ISO regorafenib results in decreased phosphorylation of MAPK3 protein CTD PMID:30801954 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mfn1 mitofusin 1 increases expression EXP regorafenib results in increased expression of MFN1 mRNA CTD PMID:33166663 NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
JBrowse link
G Mfn2 mitofusin 2 increases expression EXP regorafenib results in increased expression of MFN2 mRNA CTD PMID:33166663 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
JBrowse link
G Mmp9 matrix metallopeptidase 9 decreases expression ISO regorafenib results in decreased expression of MMP9 protein CTD PMID:30801954 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Ndufb8 NADH:ubiquinone oxidoreductase subunit B8 decreases expression EXP regorafenib results in decreased expression of NDUFB8 protein CTD PMID:33166663 NCBI chr 1:243,408,659...243,413,701
Ensembl chr 1:243,408,619...243,413,817
JBrowse link
G Opa1 OPA1, mitochondrial dynamin like GTPase increases expression EXP regorafenib results in increased expression of OPA1 mRNA CTD PMID:33166663 NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage ISO regorafenib results in increased cleavage of PARP1 protein CTD PMID:30801954 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit decreases expression ISO regorafenib results in decreased expression of RELA protein CTD PMID:30801954 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP regorafenib results in increased expression of SOD2 mRNA CTD PMID:33166663 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression ISO regorafenib results in decreased expression of VEGFA protein CTD PMID:30801954 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression ISO regorafenib results in decreased expression of XIAP protein CTD PMID:30801954 NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700
JBrowse link
sorafenib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO sorafenib results in decreased activity of ABCB11 protein CTD PMID:20829430 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 affects response to substance ISO ABCC1 affects the susceptibility to sorafenib CTD PMID:24244338 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 affects response to substance ISO ABCC2 affects the susceptibility to sorafenib CTD PMID:24244338 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 affects response to substance ISO ABCC3 affects the susceptibility to sorafenib CTD PMID:24244338 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions
decreases activity
decreases phosphorylation
ISO sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased activity of ABL1 protein mutant form
sorafenib results in decreased phosphorylation of ABL1 protein mutant form
CTD PMID:19366808 NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression EXP sorafenib results in decreased expression of ACTA2 mRNA CTD PMID:24321339 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Actg2 actin gamma 2, smooth muscle decreases expression EXP sorafenib results in decreased expression of ACTG2 mRNA CTD PMID:19338580 NCBI chr 4:116,021,832...116,046,475
Ensembl chr 4:116,021,832...116,046,465
JBrowse link
G Afp alpha-fetoprotein multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein] CTD PMID:29859236 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions
affects localization
ISO [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] affects the localization of AIFM1 protein; [sorafenib co-treated with 6-bromoindirubin-3'-oxime] affects the localization of AIFM1 protein; [sorafenib co-treated with TNFSF10 protein] affects the localization of AIFM1 protein; GSK3B inhibits the reaction [sorafenib affects the localization of AIFM1 protein]
Sorafenib affects the localization of AIFM1 protein
CTD PMID:16109713 PMID:16959960 PMID:17909059 PMID:17991738 PMID:20054642 More... NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation
decreases phosphorylation
ISO 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in decreased phosphorylation of AKT1 protein]; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Oxygen deficiency affects the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in decreased phosphorylation of AKT1 protein]]
Sorafenib results in increased phosphorylation of AKT1 protein
CTD PMID:16985072 PMID:21858812 PMID:23036488 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
ISO [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; sorafenib promotes the reaction [ATF4 protein results in increased expression of DDIT4 protein]
[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 mRNA; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 protein; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein; sorafenib results in increased expression of ATF4 mRNA; sorafenib results in increased expression of ATF4 protein
CTD PMID:21601561 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
JBrowse link
G Atg5 autophagy related 5 multiple interactions
increases expression
ISO [Sorafenib co-treated with Vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [Sorafenib co-treated with Vorinostat] results in increased expression of ATG5 protein; ATG5 protein inhibits the reaction [[Sorafenib co-treated with Vorinostat] results in increased cleavage of CASP8 protein]; EIF2AK3 protein promotes the reaction [[Sorafenib co-treated with Vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in increased expression of ATG5 protein]; FADD protein promotes the reaction [[Sorafenib co-treated with Vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in decreased expression of ATG5 protein]; FAS protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in decreased expression of ATG5 protein]
sorafenib results in increased expression of ATG5 protein
CTD PMID:18787411 NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
JBrowse link
G Bad BCL2-associated agonist of cell death increases expression
decreases expression
ISO sorafenib results in increased expression of BAD protein
sorafenib results in decreased expression of BAD mRNA
CTD PMID:18200035 PMID:21360571 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
JBrowse link
G Bak1 BCL2-antagonist/killer 1 decreases expression
multiple interactions
increases expression
ISO sorafenib results in decreased expression of BAK1 protein
[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; sorafenib promotes the reaction [destruxin B results in increased expression of BAK1 protein]
sorafenib results in increased expression of BAK1 protein
CTD PMID:16109713 PMID:17909059 PMID:18200035 PMID:24434019 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
decreases expression
increases cleavage
increases expression
ISO [sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein; [sorafenib co-treated with TNFSF10 protein] affects the localization of BAX protein; BCL2L1 protein inhibits the reaction [sorafenib affects the folding of and results in increased activity of BAX protein]; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]; sorafenib affects the folding of and results in increased activity of BAX protein
sorafenib results in decreased expression of BAX mRNA
sorafenib results in increased cleavage of BAX protein
sorafenib results in increased expression of BAX protein
CTD PMID:16109713 PMID:17909059 PMID:18200035 PMID:19366808 PMID:21360571 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases response to substance
increases cleavage
decreases expression
ISO [Paclitaxel co-treated with sorafenib] results in decreased expression of BCL2 protein; [sorafenib co-treated with Vitamin K 1] results in decreased expression of BCL2 protein; resveratrol promotes the reaction [sorafenib results in decreased expression of BCL2 protein]; sorafenib inhibits the reaction [Acids results in increased expression of BCL2 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of BCL2 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of BCL2 protein]
BCL2 protein results in decreased susceptibility to sorafenib
sorafenib results in increased cleavage of BCL2 protein
sorafenib results in decreased expression of BCL2 mRNA; sorafenib results in decreased expression of BCL2 protein
CTD PMID:16109713 PMID:17991738 PMID:18512153 PMID:19664330 PMID:19878585 More... NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
ISO [sorafenib co-treated with TNFSF10 protein] results in decreased expression of BCL2L1 protein; BCL2L1 protein inhibits the reaction [sorafenib affects the folding of and results in increased activity of BAX protein]; BCL2L1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; resveratrol promotes the reaction [sorafenib results in decreased expression of BCL2L1 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of BCL2L1 protein]
Sorafenib results in decreased expression of BCL2L1 protein
CTD PMID:16109713 PMID:17909059 PMID:17991738 PMID:19366808 PMID:19633425 More... NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bcl2l11 BCL2 like 11 affects localization
increases expression
decreases expression
multiple interactions
ISO sorafenib affects the localization of BCL2L11 protein
sorafenib results in increased expression of BCL2L11 protein
sorafenib results in decreased expression of BCL2L11 protein
[sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased expression of BCL2L11 protein
CTD PMID:16109713 PMID:18200035 PMID:23036488 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Bcr BCR activator of RhoGEF and GTPase multiple interactions
decreases phosphorylation
decreases activity
ISO sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased phosphorylation of BCR protein mutant form
sorafenib results in decreased activity of BCR protein mutant form
CTD PMID:19366808 NCBI chr20:13,471,679...13,596,497
Ensembl chr20:13,471,668...13,597,016
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of BID protein CTD PMID:17909059 PMID:20301194 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression ISO sorafenib results in decreased expression of BIRC3 protein CTD PMID:20473320 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression
ISO [[[Sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[Sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [Resveratrol co-treated with Sorafenib] results in decreased expression of BIRC5 protein; Sorafenib inhibits the reaction [IGF1 protein results in increased expression of BIRC5 protein]
sorafenib analog results in decreased expression of BIRC5 protein; sorafenib results in decreased expression of BIRC5 mRNA; sorafenib results in decreased expression of BIRC5 protein
CTD PMID:18200035 PMID:20473320 PMID:21531053 PMID:21601561 PMID:26172295 More... NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions
decreases activity
ISO
EXP
Sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]
sorafenib results in decreased activity of BRAF protein
sorafenib results in decreased activity of BRAF protein; sorafenib results in decreased activity of BRAF protein mutant form
CTD PMID:17341847 PMID:17664273 PMID:20823850 NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
JBrowse link
G Casp1 caspase 1 multiple interactions ISO N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [Sorafenib results in increased activity of CASP1 protein]; Sorafenib results in increased cleavage of and results in increased activity of CASP1 protein CTD PMID:33271325 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
decreases expression
increases cleavage
increases activity
affects cleavage
ISO [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein; [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased cleavage of CASP3 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in increased cleavage of CASP3 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of CASP3 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein; [sorafenib co-treated with vorinostat] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; arsenic trioxide promotes the reaction [sorafenib results in decreased expression of CASP3 protein]; arsenic trioxide promotes the reaction [sorafenib results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; resveratrol promotes the reaction [sorafenib results in increased cleavage of CASP3 protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased activity of CASP3 mRNA]; sorafenib promotes the reaction [arsenic trioxide results in decreased expression of CASP3 protein]; sorafenib promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]; sorafenib results in increased cleavage of and results in increased activity of CASP3 protein
Sorafenib results in increased expression of CASP3 protein modified form
sorafenib results in decreased expression of CASP3 mRNA
sorafenib affects the cleavage of CASP3 protein
CTD PMID:16007148 PMID:16109713 PMID:16985072 PMID:17909059 PMID:18200035 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp7 caspase 7 increases activity
multiple interactions
ISO sorafenib results in increased activity of CASP7 protein
[sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP7 protein; sorafenib results in increased cleavage of and results in increased activity of CASP7 protein
CTD PMID:16109713 PMID:17909059 PMID:19770576 PMID:20054642 NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage
affects localization
ISO [sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP8 protein; [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein; ATG5 protein inhibits the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; Boc-D-FMK inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP8 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; sorafenib results in increased cleavage of and results in increased activity of CASP8 protein
sorafenib results in increased cleavage of CASP8 protein
sorafenib affects the localization of CASP8 protein modified form
CTD PMID:16007148 PMID:16109713 PMID:17909059 PMID:18200035 PMID:18787411 More... NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 multiple interactions
increases cleavage
increases activity
ISO [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in increased cleavage of CASP9 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; arsenic trioxide promotes the reaction [sorafenib results in increased activity of CASP9 protein]; MCL1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP9 protein]; sorafenib promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]; sorafenib results in increased cleavage of and results in increased activity of CASP9 protein
sorafenib results in increased cleavage of CASP9 protein
CTD PMID:16109713 PMID:16985072 PMID:17909059 PMID:18200035 PMID:20054642 More... NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccn2 cellular communication network factor 2 decreases expression ISO Sorafenib results in decreased expression of CCN2 mRNA CTD PMID:21360571 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
JBrowse link
G Ccna2 cyclin A2 decreases expression ISO sorafenib results in decreased expression of CCNA2 protein CTD PMID:19139124 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO sorafenib results in decreased expression of CCNB1 protein CTD PMID:19139124 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions
ISO
EXP
sorafenib analog results in decreased expression of CCND1 protein; sorafenib results in decreased expression of CCND1 mRNA; sorafenib results in decreased expression of CCND1 protein
Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA]
sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein]; sorafenib inhibits the reaction [TSC2 protein mutant form results in increased expression of CCND1 protein]
[sorafenib co-treated with letrozole] results in decreased expression of CCND1 protein; [sorafenib co-treated with rottlerin] results in decreased expression of CCND1 protein; arsenic trioxide promotes the reaction [sorafenib results in decreased expression of CCND1 protein]; sorafenib inhibits the reaction [Acids results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Acids results in increased expression of CCND1 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]; sorafenib promotes the reaction [arsenic trioxide results in decreased expression of CCND1 protein]
CTD PMID:16959960 PMID:17178882 PMID:17909054 PMID:18512153 PMID:18840136 More... NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO sorafenib results in decreased expression of CCND2 protein CTD PMID:19001435 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
JBrowse link
G Ccnd3 cyclin D3 multiple interactions
decreases expression
ISO [sorafenib co-treated with rottlerin] results in decreased expression of CCND3 protein
sorafenib results in decreased expression of CCND3 protein
CTD PMID:16959960 PMID:19001435 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO sorafenib inhibits the reaction [Acids results in increased expression of CCNE1 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein] CTD PMID:18512153 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
JBrowse link
G Cdh1 cadherin 1 multiple interactions
increases expression
ISO sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; sorafenib promotes the reaction [destruxin B results in increased expression of CDH1 protein]
sorafenib results in increased expression of CDH1 protein
CTD PMID:21360571 PMID:24434019 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Cdh2 cadherin 2 multiple interactions ISO sorafenib promotes the reaction [destruxin B results in decreased expression of CDH2 protein] CTD PMID:24434019 NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression ISO sorafenib results in decreased expression of CDK1 protein CTD PMID:19139124 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases expression ISO sorafenib results in decreased expression of CDK2 mRNA CTD PMID:26409325 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions
decreases expression
ISO [sorafenib co-treated with rottlerin] results in decreased expression of CDK4 protein
sorafenib results in decreased expression of CDK4 protein
CTD PMID:16959960 NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
decreases expression
ISO [sorafenib co-treated with rottlerin] results in decreased expression of CDK6 protein
sorafenib results in decreased expression of CDK6 protein
CTD PMID:16959960 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
JBrowse link
G Cdk9 cyclin-dependent kinase 9 decreases expression ISO sorafenib results in decreased expression of CDK9 mRNA CTD PMID:26409325 NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression ISO sorafenib results in decreased expression of CDKN1A protein CTD PMID:19139124 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
decreases expression
increases expression
ISO
EXP
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in increased expression of CDKN1B protein]; sorafenib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of CDKN1B protein]
sorafenib results in decreased expression of CDKN1B protein
sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein]
CTD PMID:19139124 PMID:19878585 PMID:21693435 PMID:23036488 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B increases expression ISO sorafenib results in increased expression of CDKN2B protein CTD PMID:19139124 NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions
increases expression
ISO sorafenib promotes the reaction [CEBPD protein binds to GADD45G promoter]
sorafenib results in increased expression of CEBPD protein
CTD PMID:26172295 NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases expression
increases degradation
multiple interactions
ISO sorafenib results in decreased expression of CFLAR protein
sorafenib results in increased degradation of CFLAR protein
[sorafenib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [sorafenib results in decreased expression of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib results in increased degradation of CFLAR protein] which results in increased susceptibility to TNFSF10 protein
CTD PMID:17909059 PMID:20071162 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions
decreases expression
ISO
EXP
Sorafenib inhibits the reaction [Oleic Acid results in increased expression of COL1A1 mRNA]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]
sorafenib results in decreased expression of COL1A1 mRNA
CTD PMID:21360571 PMID:24321339 PMID:32918399 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 protein] CTD PMID:21360571 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
JBrowse link
G Col4a1 collagen type IV alpha 1 chain multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL4A1 protein] CTD PMID:21360571 NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of CPT1A mRNA] CTD PMID:32918399 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions
decreases phosphorylation
ISO sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased phosphorylation of CRKL protein
CTD PMID:19366808 NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO sorafenib promotes the reaction [destruxin B results in decreased expression of CTNNB1 protein] CTD PMID:24434019 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Cycs cytochrome c, somatic affects localization ISO sorafenib affects the localization of CYCS protein CTD PMID:16007148 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
JBrowse link
G Cyld CYLD lysine 63 deubiquitinase increases expression ISO [sorafenib results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein; sorafenib results in increased expression of CYLD mRNA; sorafenib results in increased expression of CYLD protein CTD PMID:21109933 NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases activity ISO Sorafenib metabolite results in decreased activity of CYP2C8 protein; Sorafenib results in decreased activity of CYP2C8 protein CTD PMID:33556367
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 mRNA; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 protein; sorafenib results in increased expression of DDIT3 mRNA; sorafenib results in increased expression of DDIT3 protein CTD PMID:17548474 PMID:21601561 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Ddit4 DNA-damage-inducible transcript 4 multiple interactions
increases expression
ISO [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; sorafenib promotes the reaction [ATF4 protein results in increased expression of DDIT4 protein]
[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein; sorafenib results in increased expression of DDIT4 protein
CTD PMID:21601561 NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein multiple interactions
affects localization
ISO 6-bromoindirubin-3'-oxime promotes the reaction [sorafenib affects the localization of DIABLO protein]; [sorafenib co-treated with TNFSF10 protein] affects the localization of DIABLO protein; GSK3B inhibits the reaction [sorafenib affects the localization of DIABLO protein]
Sorafenib affects the localization of DIABLO protein
CTD PMID:17909059 PMID:17991738 NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
JBrowse link
G Dok1 docking protein 1 decreases phosphorylation ISO sorafenib results in decreased phosphorylation of DOK1 protein CTD PMID:19366808 NCBI chr 4:115,537,453...115,540,464
Ensembl chr 4:115,537,462...115,540,465
JBrowse link
G Ece1 endothelin converting enzyme 1 increases expression EXP Sorafenib results in increased expression of ECE1 protein CTD PMID:33503445 NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371
JBrowse link
G Edn1 endothelin 1 increases expression EXP Sorafenib results in increased expression of EDN1 protein CTD PMID:33503445 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Ednrb endothelin receptor type B increases expression EXP Sorafenib results in increased expression of EDNRB mRNA; Sorafenib results in increased expression of EDNRB protein CTD PMID:33503445 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
JBrowse link
G Egf epidermal growth factor multiple interactions ISO [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:17664273 PMID:21187475 NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Egfr epidermal growth factor receptor decreases expression ISO sorafenib results in decreased expression of EGFR mRNA CTD PMID:26409325 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A multiple interactions
increases phosphorylation
ISO [sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]
sorafenib results in increased phosphorylation of EIF2A protein
CTD PMID:17548474 PMID:18787411 PMID:19366808 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions
increases phosphorylation
ISO [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to EIF2AK3 protein]; [sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased expression of ATG5 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]
sorafenib results in increased phosphorylation of EIF2AK3 protein
CTD PMID:17548474 PMID:18787411 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
JBrowse link
G Eif4e eukaryotic translation initiation factor 4E multiple interactions
decreases phosphorylation
ISO [sorafenib results in decreased phosphorylation of EIF4E protein] which results in decreased expression of MCL1; sorafenib inhibits the reaction [MKNK1 protein results in increased phosphorylation of EIF4E protein] CTD PMID:16109713 PMID:21750559 NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
increases phosphorylation
decreases phosphorylation
ISO
EXP
[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib] results in decreased phosphorylation of EIF4EBP1 protein; arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of EIF4EBP1 protein]
sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of EIF4EBP1 protein modified form]
Sorafenib results in decreased phosphorylation of EIF4EBP1 protein
CTD PMID:16255777 PMID:20054642 PMID:21601561 PMID:21813464 PMID:21858812 More... NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Fadd Fas associated via death domain multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in decreased expression of ATG5 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein] CTD PMID:18787411 NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
JBrowse link
G Fas Fas cell surface death receptor multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to EIF2AK3 protein]; [vorinostat co-treated with sorafenib] affects the localization of FAS protein; [vorinostat co-treated with sorafenib] results in increased activity of FAS protein; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in decreased expression of ATG5 protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]; fumonisin B1 inhibits the reaction [[sorafenib co-treated with vorinostat] affects the localization of and results in increased activity of FAS protein]; SMPD1 protein promotes the reaction [[vorinostat co-treated with sorafenib] affects the localization of FAS protein]; thermozymocidin inhibits the reaction [[sorafenib co-treated with vorinostat] affects the localization of and results in increased activity of FAS protein] CTD PMID:18787411 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
JBrowse link
G Faslg Fas ligand multiple interactions ISO [sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein] CTD PMID:20301194 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Flt3 Fms related receptor tyrosine kinase 3 increases response to substance
decreases phosphorylation
multiple interactions
decreases activity
ISO FLT3 protein results in increased susceptibility to sorafenib
sorafenib results in decreased phosphorylation of FLT3 protein mutant form
[sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of FLT3 protein mutant form; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK3 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of FLT3 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK3 protein; sorafenib inhibits the reaction [FLT3 protein mutant form results in increased phosphorylation of FLT3 protein mutant form]
sorafenib results in decreased activity of FLT3 protein; sorafenib results in decreased activity of FLT3 protein mutant form
CTD PMID:17205056 PMID:17229632 PMID:21482694 PMID:22409268 PMID:23036488 NCBI chr12:7,623,658...7,699,474
Ensembl chr12:7,623,930...7,699,474
JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein] CTD PMID:21360571 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta multiple interactions
increases expression
increases response to substance
ISO pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B mRNA]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B protein]; sorafenib promotes the reaction [JUN protein binds to GADD45B promoter]; sorafenib results in increased expression of and results in increased localization of GADD45B protein
GADD45B protein results in increased susceptibility to sorafenib
CTD PMID:21062976 NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma decreases response to substance
increases expression
multiple interactions
ISO GADD45G mutant form results in decreased susceptibility to sorafenib
sorafenib results in increased expression of GADD45G mRNA; sorafenib results in increased expression of GADD45G protein
sorafenib promotes the reaction [CEBPD protein binds to GADD45G promoter]
CTD PMID:26172295 NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions
increases secretion
ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased activity of GPT protein]
Sorafenib results in increased secretion of GPT protein
CTD PMID:29655783 PMID:29859236 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Grb2 growth factor receptor bound protein 2 decreases expression ISO sorafenib results in decreased expression of GRB2 mRNA CTD PMID:26409325 NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309
JBrowse link
G Gsdmd gasdermin D increases expression ISO Sorafenib results in increased expression of GSDMD protein CTD PMID:33271325 NCBI chr 7:107,542,242...107,547,052
Ensembl chr 7:107,542,083...107,547,055
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions
increases phosphorylation
ISO arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of GSK3B protein]; GSK3B inhibits the reaction [sorafenib affects the localization of AIFM1 protein]; GSK3B inhibits the reaction [sorafenib affects the localization of DIABLO protein]; sorafenib inhibits the reaction [arsenic trioxide results in decreased phosphorylation of GSK3B protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of MYC protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of TP53 protein]; sorafenib results in decreased phosphorylation of and results in increased activity of GSK3B protein CTD PMID:17991738 PMID:25416439 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
JBrowse link
G Hdac6 histone deacetylase 6 decreases expression ISO sorafenib results in decreased expression of HDAC6 mRNA CTD PMID:26409325 NCBI chr  X:14,550,645...14,572,445
Ensembl chr  X:14,551,044...14,572,441
JBrowse link
G Hgf hepatocyte growth factor decreases response to substance
multiple interactions
ISO HGF protein results in decreased susceptibility to Sorafenib
Plant Extracts inhibits the reaction [HGF protein results in decreased susceptibility to Sorafenib]
CTD PMID:32522589 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha decreases expression ISO sorafenib results in decreased expression of HIF1A mRNA CTD PMID:26409325 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
JBrowse link
G Hmgb1 high mobility group box 1 increases expression ISO Sorafenib results in increased expression of HMGB1 protein CTD PMID:33271325 NCBI chr12:5,973,062...5,978,565 JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]] CTD PMID:18787411 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO sorafenib inhibits the reaction [IGF1 protein results in increased expression of BIRC5 protein] CTD PMID:21601561 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
JBrowse link
G Igf1r insulin-like growth factor 1 receptor decreases expression ISO sorafenib results in decreased expression of IGF1R mRNA CTD PMID:26409325 NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
JBrowse link
G Il1b interleukin 1 beta increases secretion
multiple interactions
ISO Sorafenib results in increased secretion of IL1B protein
N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [Sorafenib results in increased secretion of IL1B protein]
CTD PMID:33271325 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in increased expression of IL6 protein] CTD PMID:32918399 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Irf5 interferon regulatory factor 5 increases expression ISO sorafenib results in increased expression of IRF5 mRNA CTD PMID:26409325 NCBI chr 4:58,127,577...58,140,665
Ensembl chr 4:58,127,640...58,139,267
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
ISO [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; [sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of JUN protein]; sorafenib promotes the reaction [JUN protein binds to GADD45B promoter]; sorafenib results in increased expression of and results in increased phosphorylation of and results in increased localization of JUN protein CTD PMID:16985072 PMID:20301194 PMID:21062976 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO sorafenib results in decreased activity of KCNH2 protein CTD PMID:28551711 NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
JBrowse link
G Kdr kinase insert domain receptor multiple interactions
decreases phosphorylation
ISO [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein
sorafenib results in decreased phosphorylation of KDR protein
CTD PMID:16985072 PMID:19139124 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase decreases phosphorylation ISO sorafenib results in decreased phosphorylation of KIT protein CTD PMID:19139124 NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase decreases phosphorylation ISO sorafenib results in decreased phosphorylation of LCK protein CTD PMID:21293487 NCBI chr 5:141,888,319...141,916,992
Ensembl chr 5:141,888,326...141,903,794
JBrowse link
G Lipc lipase C, hepatic type multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of LIPC mRNA] CTD PMID:32918399 NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions
decreases phosphorylation
ISO
EXP
[MAP2K1 protein results in increased phosphorylation of MAPK1 protein] which results in decreased susceptibility to sorafenib; [MAP2K1 protein results in increased phosphorylation of MAPK3 protein] which results in decreased susceptibility to sorafenib; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]
sorafenib results in decreased phosphorylation of MAP2K1 protein
CTD PMID:17341847 PMID:18200035 PMID:19139124 PMID:20117835 PMID:21187475 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions
decreases phosphorylation
ISO
EXP
[sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]
sorafenib results in decreased phosphorylation of MAP2K2 protein
CTD PMID:17341847 PMID:18200035 PMID:21187475 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
JBrowse link
G Map2k4 mitogen activated protein kinase kinase 4 multiple interactions
decreases phosphorylation
ISO licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAP2K4 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAP2K4 protein] CTD PMID:30187994 NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
JBrowse link
G Mapk1 mitogen activated protein kinase 1 affects phosphorylation
increases phosphorylation
decreases phosphorylation
multiple interactions
decreases expression
decreases activity
ISO
EXP
sorafenib affects the phosphorylation of MAPK1 protein
sorafenib results in increased phosphorylation of MAPK1 protein
sorafenib results in decreased phosphorylation of MAPK1 protein
Sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK1 protein modified form]; Sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
sorafenib results in decreased expression of MAPK1 protein modified form
Sorafenib results in decreased phosphorylation of MAPK1 protein
sorafenib results in decreased activity of MAPK1 protein
[MAP2K1 protein results in increased phosphorylation of MAPK1 protein] which results in decreased susceptibility to sorafenib; [sorafenib co-treated with [IFNA2 protein co-treated with IFNA8 protein]] affects the phosphorylation of MAPK1 protein; [sorafenib co-treated with Cisplatin] results in decreased phosphorylation of MAPK1 protein; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [sorafenib co-treated with rottlerin] results in decreased phosphorylation of MAPK1 protein; [sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK1 protein; sorafenib inhibits the reaction [arsenic trioxide results in increased activity of MAPK1 protein]; sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
CTD PMID:16109713 PMID:16255777 PMID:16959960 PMID:17178882 PMID:17205056 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk14 mitogen activated protein kinase 14 decreases expression ISO sorafenib results in decreased expression of MAPK14 protein modified form CTD PMID:16985072 NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
decreases expression
decreases phosphorylation
decreases activity
affects phosphorylation
ISO
EXP
[MAP2K1 protein results in increased phosphorylation of MAPK3 protein] which results in decreased susceptibility to sorafenib; [sorafenib co-treated with [IFNA2 protein co-treated with IFNA8 protein]] affects the phosphorylation of MAPK3 protein; [sorafenib co-treated with Cisplatin] results in decreased phosphorylation of MAPK3 protein; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [sorafenib co-treated with rottlerin] results in decreased phosphorylation of MAPK3 protein; [sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK3 protein; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK3 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK3 protein; sorafenib inhibits the reaction [Acids results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [arsenic trioxide results in increased activity of MAPK3 protein]; sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
sorafenib results in increased phosphorylation of MAPK3 protein
sorafenib results in decreased expression of MAPK3 protein modified form
sorafenib results in decreased phosphorylation of MAPK3 protein
sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK3 protein modified form]; sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
Sorafenib results in decreased phosphorylation of MAPK3 protein
sorafenib results in decreased activity of MAPK3 protein
sorafenib affects the phosphorylation of MAPK3 protein
CTD PMID:16109713 PMID:16255777 PMID:16959960 PMID:17178882 PMID:17205056 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
decreases phosphorylation
ISO [Bortezomib co-treated with Sorafenib] results in increased phosphorylation of MAPK8 protein; licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAPK8 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAPK8 protein] CTD PMID:16985072 PMID:30187994 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions
decreases phosphorylation
ISO [Bortezomib co-treated with Sorafenib] results in increased phosphorylation of MAPK9 protein; licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAPK9 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAPK9 protein] CTD PMID:16985072 PMID:30187994 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
affects response to substance
increases degradation
decreases expression
decreases response to substance
ISO [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased expression of MCL1 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in decreased expression of MCL1 mRNA; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in decreased expression of MCL1 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein; [sorafenib co-treated with TNFSF10 protein] results in decreased expression of MCL1 protein; [sorafenib results in decreased phosphorylation of EIF4E protein] which results in decreased expression of MCL1; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]; MCL1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP9 protein]; MCL1 protein results in decreased susceptibility to [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide]; sorafenib results in increased degradation of and results in decreased expression of MCL1 protein
MCL1 protein affects the susceptibility to sorafenib
sorafenib results in increased degradation of MCL1 protein
sorafenib results in decreased expression of MCL1 protein
MCL1 protein results in decreased susceptibility to sorafenib
CTD PMID:16007148 PMID:16109713 PMID:16985072 PMID:17178882 PMID:17595328 More... NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO sorafenib results in increased expression of MDM2 mRNA CTD PMID:26409325 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
JBrowse link
G Mknk1 MAPK interacting serine/threonine kinase 1 multiple interactions ISO sorafenib inhibits the reaction [MKNK1 protein results in increased phosphorylation of EIF4E protein] CTD PMID:16109713 NCBI chr 5:129,318,128...129,357,641
Ensembl chr 5:129,318,170...129,357,639
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein] CTD PMID:29859236 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Msn moesin increases phosphorylation EXP sorafenib results in increased phosphorylation of MSN protein CTD PMID:19338580 NCBI chr  X:60,996,043...61,064,011
Ensembl chr  X:60,995,951...61,065,628
JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases activity
increases phosphorylation
increases expression
decreases phosphorylation
multiple interactions
decreases expression
ISO sorafenib results in decreased activity of MTOR protein
sorafenib results in increased phosphorylation of MTOR protein
sorafenib results in increased expression of MTOR protein
sorafenib results in decreased phosphorylation of MTOR protein
[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib] results in decreased activity of MTOR protein; [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; [sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; arsenic trioxide inhibits the reaction [sorafenib results in increased expression of MTOR protein]
sorafenib results in decreased expression of MTOR mRNA
CTD PMID:20054642 PMID:21187475 PMID:21601561 PMID:23036488 PMID:25416439 More... NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Mttp microsomal triglyceride transfer protein multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of MTTP mRNA] CTD PMID:32918399 NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [sorafenib co-treated with letrozole] results in decreased expression of MYC protein; sorafenib inhibits the reaction [Acids results in increased expression of MYC protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of MYC protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of MYC protein] CTD PMID:17991738 PMID:18512153 PMID:20054642 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in decreased expression of NFKB1 protein] CTD PMID:29859236 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression ISO [sorafenib results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein CTD PMID:21109933 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nos2 nitric oxide synthase 2 decreases expression EXP Sorafenib results in decreased expression of NOS2 mRNA CTD PMID:33503445 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nos3 nitric oxide synthase 3 decreases expression EXP Sorafenib results in decreased expression of NOS3 mRNA CTD PMID:33503445 NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
JBrowse link
G Nras NRAS proto-oncogene, GTPase decreases expression ISO sorafenib results in decreased expression of NRAS mRNA CTD PMID:26409325 NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO [Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein; [sorafenib co-treated with PRKN protein] results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; resveratrol promotes the reaction [sorafenib results in increased cleavage of PARP1 protein] CTD PMID:16985072 PMID:20054642 PMID:26911335 PMID:28673964 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pdgfb platelet derived growth factor subunit B multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in increased expression of PDGFB mRNA] CTD PMID:32918399 NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
JBrowse link
G Pdgfra platelet derived growth factor receptor alpha decreases phosphorylation ISO sorafenib results in decreased phosphorylation of PDGFRA protein mutant form CTD PMID:21482694 NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335
JBrowse link
G Pdgfrb platelet derived growth factor receptor beta multiple interactions
decreases expression
decreases phosphorylation
decreases activity
ISO
EXP
[Bortezomib co-treated with sorafenib] results in decreased phosphorylation of PDGFRB protein
sorafenib results in decreased phosphorylation of and results in decreased activity of PDGFRB protein
sorafenib results in decreased expression of PDGFRB mRNA
sorafenib results in decreased phosphorylation of PDGFRB protein
sorafenib results in decreased activity of PDGFRB protein mutant form
CTD PMID:16985072 PMID:17229632 PMID:19139124 PMID:19338580 NCBI chr18:54,500,002...54,538,843
Ensembl chr18:54,499,964...54,538,843
JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 decreases expression EXP Sorafenib results in decreased expression of PECAM1 protein CTD PMID:33503445 NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
JBrowse link
G Pik3c2a phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha decreases expression ISO sorafenib results in decreased expression of PIK3C2A mRNA CTD PMID:26409325 NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472
JBrowse link
G Pik3ca phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha decreases expression ISO sorafenib results in decreased expression of PIK3CA mRNA CTD PMID:26409325 NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase multiple interactions ISO [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib co-treated with Oxygen deficiency] results in decreased expression of PIM1 protein; [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] inhibits the reaction [Oxygen deficiency results in increased expression of PIM1 protein]; [sorafenib co-treated with Oxygen deficiency] results in decreased expression of PIM1 protein; sorafenib inhibits the reaction [Oxygen deficiency results in increased expression of PIM1 protein] CTD PMID:23036488 NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174
JBrowse link
G Pink1 PTEN induced kinase 1 multiple interactions
increases expression
affects response to substance
ISO [sorafenib co-treated with PRKN protein] results in increased expression of PINK1 protein; PINK1 protein affects the reaction [sorafenib affects the localization of PRKN protein]
sorafenib results in increased expression of PINK1 protein
PINK1 protein affects the susceptibility to sorafenib
CTD PMID:28673964 NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
JBrowse link
G Plau plasminogen activator, urokinase decreases expression
multiple interactions
ISO Sorafenib results in decreased expression of PLAU protein
licochalcone A promotes the reaction [Sorafenib results in decreased expression of PLAU protein]; Sorafenib promotes the reaction [licochalcone A results in decreased expression of PLAU protein]
CTD PMID:30187994 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
JBrowse link
G Plk2 polo-like kinase 2 increases expression ISO sorafenib results in increased expression of PLK2 mRNA CTD PMID:26409325 NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947
JBrowse link
G Plk3 polo-like kinase 3 increases expression ISO sorafenib results in increased expression of PLK3 mRNA CTD PMID:26409325 NCBI chr 5:130,607,142...130,612,317
Ensembl chr 5:130,607,142...130,612,317
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 multiple interactions
decreases expression
ISO 6-bromoindirubin-3'-oxime inhibits the reaction [sorafenib results in decreased expression of PMAIP1 protein] CTD PMID:17991738 NCBI chr18:59,986,187...59,990,174
Ensembl chr18:59,986,017...59,992,429
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO sorafenib results in increased expression of PPP1R15A protein CTD PMID:17548474 NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
JBrowse link
G Prkca protein kinase C, alpha decreases expression ISO sorafenib results in decreased expression of PRKCA mRNA CTD PMID:26409325 NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase increases ubiquitination
affects response to substance
multiple interactions
affects localization
ISO sorafenib results in increased ubiquitination of PRKN protein
PRKN protein affects the susceptibility to sorafenib
[sorafenib co-treated with PRKN protein] results in decreased expression of CASP3 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein; [sorafenib co-treated with PRKN protein] results in increased cleavage of PARP1 protein; [sorafenib co-treated with PRKN protein] results in increased expression of PINK1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; PINK1 protein affects the reaction [sorafenib affects the localization of PRKN protein]
CTD PMID:28673964 NCBI chr 1:48,688,651...49,882,520 JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase decreases activity ISO sorafenib results in decreased activity of RAF1 protein CTD PMID:19139124 PMID:21531053 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases expression
decreases phosphorylation
ISO [sorafenib co-treated with letrozole] results in decreased expression of RB1 protein
sorafenib results in decreased expression of RB1 protein
sorafenib results in decreased phosphorylation of RB1 protein
CTD PMID:17909054 PMID:19633425 PMID:20054642 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of RELA protein] CTD PMID:29859236 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Ret ret proto-oncogene decreases activity
increases degradation
ISO Sorafenib results in decreased activity of RET protein; Sorafenib results in decreased activity of RET protein mutant form
sorafenib results in increased degradation of RET protein
CTD PMID:17664273 NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
JBrowse link
G Rock1 Rho-associated coiled-coil containing protein kinase 1 decreases expression
increases expression
EXP sorafenib results in decreased expression of ROCK1 mRNA; sorafenib results in decreased expression of ROCK1 protein
sorafenib results in increased expression of ROCK1 protein
CTD PMID:19338580 NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
multiple interactions
ISO sorafenib results in decreased phosphorylation of RPS6 protein
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in decreased phosphorylation of RPS6 protein]
CTD PMID:23036488 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions
decreases phosphorylation
increases phosphorylation
ISO arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of RPS6KB1 protein]
Sorafenib results in decreased phosphorylation of RPS6KB1 protein
CTD PMID:21858812 PMID:25416439 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
JBrowse link
G Serpinh1 serpin family H member 1 decreases expression EXP sorafenib results in decreased expression of SERPINH1 mRNA CTD PMID:24321339 NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
JBrowse link
G Sesn2 sestrin 2 increases expression ISO Sorafenib results in increased expression of SESN2 protein CTD PMID:31323261 NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
JBrowse link
G Slc13a5 solute carrier family 13 member 5 decreases response to substance ISO SLC13A5 protein results in decreased susceptibility to Sorafenib CTD PMID:32634519 NCBI chr10:56,866,249...56,891,189
Ensembl chr10:56,866,249...56,890,945
JBrowse link
G Smad2 SMAD family member 2 affects localization
multiple interactions
ISO sorafenib affects the localization of SMAD2 protein
sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]
CTD PMID:21360571 NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
JBrowse link
G Smad3 SMAD family member 3 affects localization
multiple interactions
ISO sorafenib affects the localization of SMAD3 protein
sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]
CTD PMID:21360571 NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
JBrowse link
G Smad7 SMAD family member 7 decreases expression ISO sorafenib results in decreased expression of SMAD7 mRNA CTD PMID:21360571 NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765
JBrowse link
G Smpd1 sphingomyelin phosphodiesterase 1 multiple interactions ISO [vorinostat co-treated with sorafenib] promotes the reaction [SMPD1 protein results in increased abundance of Ceramides]; SMPD1 protein promotes the reaction [[vorinostat co-treated with sorafenib] affects the localization of FAS protein] CTD PMID:18787411 NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794
JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein] CTD PMID:21360571 NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions
decreases expression
ISO destruxin B promotes the reaction [sorafenib results in decreased expression of SNAI2 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of SNAI2 protein] CTD PMID:24434019 NCBI chr11:86,183,800...86,186,109
Ensembl chr11:86,181,909...86,186,200
JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO sorafenib results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression
ISO bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein] CTD PMID:21858812 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions
decreases activity
ISO sorafenib inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein]
sorafenib results in decreased activity of SRC protein
CTD PMID:20881478 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
affects localization
decreases phosphorylation
ISO resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [Acids results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of STAT3 protein]; sorafenib results in decreased phosphorylation of and results in decreased activity of STAT3 protein
sorafenib affects the localization of STAT3 protein
sorafenib analog results in decreased phosphorylation of STAT3 protein; sorafenib results in decreased phosphorylation of STAT3 protein
CTD PMID:18512153 PMID:19001435 PMID:20881478 PMID:21360571 PMID:21531053 More... NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Stat5a signal transducer and activator of transcription 5A decreases phosphorylation
multiple interactions
decreases activity
ISO sorafenib results in decreased phosphorylation of STAT5A protein
resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT5A protein]
sorafenib results in decreased activity of STAT5A protein
CTD PMID:17595328 PMID:23036488 PMID:26911335 NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
JBrowse link
G Stat5b signal transducer and activator of transcription 5B multiple interactions ISO resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT5B protein] CTD PMID:26911335 NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668
JBrowse link
G Stc1 stanniocalcin 1 decreases expression
multiple interactions
ISO sorafenib results in decreased expression of STC1 mRNA
STC1 affects the reaction [sorafenib results in increased abundance of Reactive Oxygen Species]
CTD PMID:25370841 NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
decreases expression
decreases activity
ISO Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TGFB1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of TJP1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased activity of CASP3 mRNA]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL4A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of STAT3 protein]
sorafenib results in decreased expression of TGFB1 mRNA
sorafenib results in decreased activity of TGFB1 protein
Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of TGFB1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]
CTD PMID:21360571 PMID:29859236 PMID:32918399 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TIMP1 mRNA] CTD PMID:32918399 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664
JBrowse link
G Timp3 TIMP metallopeptidase inhibitor 3 decreases expression ISO sorafenib results in decreased expression of TIMP3 mRNA CTD PMID:21360571 NCBI chr 7:17,520,827...17,571,871
Ensembl chr 7:17,521,919...17,571,839
JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of TJP1 protein] CTD PMID:21360571 NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of TNF protein]
Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TNF protein]
CTD PMID:29859236 PMID:32918399 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions
increases response to substance
ISO [[Sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein; [Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of AIFM1 protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of BAX protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of DIABLO protein; [Sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of BCL2L1 protein; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of MCL1 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP7 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of XIAP protein; [Sorafenib results in decreased expression of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; [Sorafenib results in increased degradation of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; MCL1 protein inhibits the reaction [[Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; MCL1 protein inhibits the reaction [[Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]
sorafenib results in increased susceptibility to TNFSF10 protein
CTD PMID:17909059 PMID:20071162 PMID:21601561 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of TP53 protein] CTD PMID:17991738 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Tsc2 TSC complex subunit 2 multiple interactions EXP sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of EIF4EBP1 protein modified form]; sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK1 protein modified form]; sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK3 protein modified form]; sorafenib inhibits the reaction [TSC2 protein mutant form results in increased expression of CCND1 protein] CTD PMID:21813464 NCBI chr10:13,621,135...13,655,773
Ensembl chr10:13,621,136...13,655,951
JBrowse link
G Twist1 twist family bHLH transcription factor 1 decreases expression ISO sorafenib results in decreased expression of TWIST1 mRNA CTD PMID:21360571 NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
JBrowse link
G Txnrd1 thioredoxin reductase 1 increases expression ISO sorafenib results in increased expression of TXNRD1 mRNA CTD PMID:26409325 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of VEGFA protein] CTD PMID:29859236 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Vim vimentin multiple interactions
decreases expression
ISO destruxin B promotes the reaction [sorafenib results in decreased expression of VIM protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of VIM protein] CTD PMID:21360571 PMID:24434019 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
JBrowse link
G Xbp1 X-box binding protein 1 increases splicing ISO sorafenib results in increased splicing of XBP1 mRNA CTD PMID:17548474 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression
increases cleavage
multiple interactions
ISO sorafenib results in decreased expression of XIAP protein
sorafenib results in increased cleavage of XIAP protein
[sorafenib co-treated with TNFSF10 protein] results in increased cleavage of XIAP protein
CTD PMID:16109713 PMID:17909059 PMID:18200035 NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700
JBrowse link
G Yap1 Yes1 associated transcriptional regulator decreases response to substance ISO YAP1 protein results in decreased susceptibility to sorafenib CTD PMID:29698666 NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010
JBrowse link
G Zeb1 zinc finger E-box binding homeobox 1 decreases expression ISO sorafenib results in decreased expression of ZEB1 mRNA CTD PMID:21360571 NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
JBrowse link
G Zeb2 zinc finger E-box binding homeobox 2 decreases expression ISO sorafenib results in decreased expression of ZEB2 mRNA CTD PMID:21360571 NCBI chr 3:29,219,765...29,342,094
Ensembl chr 3:29,218,301...29,345,157
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19800
    chemical entity 19800
      atom 19799
        nonmetal atom 19686
          nitrogen atom 18767
            nitrogen molecular entity 18767
              organonitrogen compound 18544
                carboxamide 17285
                  pyridinecarboxamide 303
                    1-(4-bromo-2-chlorophenyl)-3-[[oxo(pyridin-4-yl)methyl]amino]thiourea 0
                    1-[(2-chlorophenyl)methyl]-2-oxo-6-(trifluoromethyl)-3-pyridinecarboxamide 0
                    1-[3-(1-\{[5-(2-phenylethyl)pyridin-3-yl]carbonyl\}piperidin-4-yl)phenyl]methanamine 0
                    1-[[oxo(3-pyridinyl)methyl]amino]-3-(4-propan-2-ylphenyl)thiourea 0
                    1-ribosyl-imidazolenicotinamide 0
                    2-(2,4-dimethylanilino)-N-(thiophen-2-ylmethyl)-3-pyridinecarboxamide 0
                    2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide 0
                    2-(4-chloro-2-methylanilino)-3-pyridinecarboxamide 0
                    2-methylnicotinamide 0
                    2-oxo-N-(2-thiazolyl)-1H-pyridine-3-carboxamide 0
                    2-tert-butyl-N-(phenylmethyl)-4-pyridinecarboxamide 0
                    3-[(2,2-dimethylpropanoyl)amino]-N-1,3-thiazol-2-ylpyridine-2-carboxamide 0
                    5-bromo-N-(4-methyl-2-thiazolyl)-3-pyridinecarboxamide 0
                    5-bromo-N-[(2-pyridinylamino)-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                    5-bromo-N-[(5-nitro-2-thiophenyl)methylideneamino]-3-pyridinecarboxamide 0
                    5-bromo-N-[[(3-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                    5-bromo-N-[[(4-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                    5-hydroxy-N-[2-[[(5-hydroxy-3-pyridinyl)-oxomethyl]amino]propyl]-3-pyridinecarboxamide 0
                    5-pentyl-N-\{[4'-(piperidin-1-ylcarbonyl)biphenyl-4-yl]methyl\}-N-[1-(pyridin-2-ylmethyl)piperidin-4-yl]pyridin-2-carboxamide 0
                    6-Methylnicotinamide 0
                    6-methyl-N-(2-pyridinylmethylideneamino)-3-pyridinecarboxamide 0
                    6-methyl-N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
                    Boscalid Glc ac a and b 0
                    CGP-42112A 7
                    DCC-2036 0
                    LSM-10636 0
                    LSM-11859 0
                    LSM-12441 0
                    LSM-12531 0
                    LSM-42129 0
                    LSM-9039 0
                    LSM-9505 0
                    LSM-9579 0
                    Lazabemide hydrochloride 0
                    Mercapturic conjugation of Boscalid 0
                    N-(1-adamantyl)-5-hydroxy-3-pyridinecarboxamide 0
                    N-(3-\{[7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]amino\}-4-methylphenyl)-2-morpholin-4-ylisonicotinamide 0
                    N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-2-carboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                    N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-4-carboxamide 0
                    N-[(2S,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-2-carboxamide 0
                    N-[(3,3-dimethyl-5-oxocyclohexylidene)amino]-3-pyridinecarboxamide 0
                    N-[1,1,1,3,3,3-hexafluoro-2-(2-pyridinylmethylamino)propan-2-yl]-3-pyridinecarboxamide 0
                    N-[2-(3,4-diethoxyphenyl)ethyl]-2-pyridinecarboxamide 0
                    N-[2-[2-[2-[[oxo(3-pyridinyl)methyl]amino]ethoxy]ethoxy]ethyl]-3-pyridinecarboxamide 0
                    N-[3-[(phenylmethyl)amino]propyl]-2-pyridinecarboxamide 0
                    N-[4-methyl-6-(1-oxobutylamino)-3-pyridinyl]-4-pyridinecarboxamide 0
                    N-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]-3-pyridinecarboxamide 0
                    N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
                    N-[5-[(3-methoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-3-thiazolidinyl]-4-pyridinecarboxamide 0
                    N-[6-(1-oxopentylamino)-3-pyridinyl]-3-pyridinecarboxamide 0
                    N-[6-[[cyclohexyl(oxo)methyl]amino]-3-pyridinyl]-2-pyridinecarboxamide 0
                    N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5R)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5R)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5S)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5S)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5S)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5S)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[3-methoxy-4-[2-(4-methylanilino)-2-oxoethoxy]phenyl]methylideneamino]-3-pyridinecarboxamide 0
                    N-[[5-(4-nitrophenyl)-2-furanyl]methylideneamino]-3-pyridinecarboxamide 0
                    N-\{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl\}pyridine-3-carboxamide 0
                    N-hydroxy-4-pyridinecarboxamide 0
                    N-methyl-4-pyridone-3-carboxamide + 0
                    N-methyl-6-pyridone-3-carboxamide + 1
                    N-methyl-N-[5-(3-pyridinyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
                    N-methylnicotinamide 2
                    N-ribosyl-4-pyridone-3-carboxamide 0
                    Nicoxamat 0
                    acetic acid 2-[[oxo(3-pyridinyl)methyl]amino]ethyl ester 0
                    boscalid + 0
                    caerulomycin I 0
                    caerulomycinamide 0
                    cyclobutrifluram 0
                    diflufenican 0
                    flonicamid 0
                    florylpicoxamid 0
                    hydroxymethylnicotinamide 0
                    isonicotinamide + 8
                    motesanib 0
                    nicorandil 18
                    nicotinamide + 140
                    nikethamide 0
                    picolinafen 0
                    picolinamide 0
                    regorafenib + 22
                    sorafenib + 173
                    tert-butyl [2-(1,3-thiazol-2-ylcarbamoyl)pyridin-3-yl]carbamate 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19800
    subatomic particle 19799
      composite particle 19799
        hadron 19799
          baryon 19799
            nucleon 19799
              atomic nucleus 19799
                atom 19799
                  main group element atom 19698
                    p-block element atom 19698
                      carbon group element atom 19619
                        carbon atom 19609
                          organic molecular entity 19609
                            organic group 18718
                              organic divalent group 18702
                                organodiyl group 18702
                                  carbonyl group 18651
                                    carbonyl compound 18651
                                      carboxylic acid 18346
                                        carboacyl group 17469
                                          univalent carboacyl group 17469
                                            carbamoyl group 17285
                                              carboxamide 17285
                                                pyridinecarboxamide 303
                                                  1-(4-bromo-2-chlorophenyl)-3-[[oxo(pyridin-4-yl)methyl]amino]thiourea 0
                                                  1-[(2-chlorophenyl)methyl]-2-oxo-6-(trifluoromethyl)-3-pyridinecarboxamide 0
                                                  1-[3-(1-\{[5-(2-phenylethyl)pyridin-3-yl]carbonyl\}piperidin-4-yl)phenyl]methanamine 0
                                                  1-[[oxo(3-pyridinyl)methyl]amino]-3-(4-propan-2-ylphenyl)thiourea 0
                                                  1-ribosyl-imidazolenicotinamide 0
                                                  2-(2,4-dimethylanilino)-N-(thiophen-2-ylmethyl)-3-pyridinecarboxamide 0
                                                  2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide 0
                                                  2-(4-chloro-2-methylanilino)-3-pyridinecarboxamide 0
                                                  2-methylnicotinamide 0
                                                  2-oxo-N-(2-thiazolyl)-1H-pyridine-3-carboxamide 0
                                                  2-tert-butyl-N-(phenylmethyl)-4-pyridinecarboxamide 0
                                                  3-[(2,2-dimethylpropanoyl)amino]-N-1,3-thiazol-2-ylpyridine-2-carboxamide 0
                                                  5-bromo-N-(4-methyl-2-thiazolyl)-3-pyridinecarboxamide 0
                                                  5-bromo-N-[(2-pyridinylamino)-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                                                  5-bromo-N-[(5-nitro-2-thiophenyl)methylideneamino]-3-pyridinecarboxamide 0
                                                  5-bromo-N-[[(3-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                                                  5-bromo-N-[[(4-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                                                  5-hydroxy-N-[2-[[(5-hydroxy-3-pyridinyl)-oxomethyl]amino]propyl]-3-pyridinecarboxamide 0
                                                  5-pentyl-N-\{[4'-(piperidin-1-ylcarbonyl)biphenyl-4-yl]methyl\}-N-[1-(pyridin-2-ylmethyl)piperidin-4-yl]pyridin-2-carboxamide 0
                                                  6-Methylnicotinamide 0
                                                  6-methyl-N-(2-pyridinylmethylideneamino)-3-pyridinecarboxamide 0
                                                  6-methyl-N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
                                                  Boscalid Glc ac a and b 0
                                                  CGP-42112A 7
                                                  DCC-2036 0
                                                  LSM-10636 0
                                                  LSM-11859 0
                                                  LSM-12441 0
                                                  LSM-12531 0
                                                  LSM-42129 0
                                                  LSM-9039 0
                                                  LSM-9505 0
                                                  LSM-9579 0
                                                  Lazabemide hydrochloride 0
                                                  Mercapturic conjugation of Boscalid 0
                                                  N-(1-adamantyl)-5-hydroxy-3-pyridinecarboxamide 0
                                                  N-(3-\{[7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]amino\}-4-methylphenyl)-2-morpholin-4-ylisonicotinamide 0
                                                  N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-2-carboxamide 0
                                                  N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                                                  N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                                                  N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-4-carboxamide 0
                                                  N-[(2S,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                                                  N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-2-carboxamide 0
                                                  N-[(3,3-dimethyl-5-oxocyclohexylidene)amino]-3-pyridinecarboxamide 0
                                                  N-[1,1,1,3,3,3-hexafluoro-2-(2-pyridinylmethylamino)propan-2-yl]-3-pyridinecarboxamide 0
                                                  N-[2-(3,4-diethoxyphenyl)ethyl]-2-pyridinecarboxamide 0
                                                  N-[2-[2-[2-[[oxo(3-pyridinyl)methyl]amino]ethoxy]ethoxy]ethyl]-3-pyridinecarboxamide 0
                                                  N-[3-[(phenylmethyl)amino]propyl]-2-pyridinecarboxamide 0
                                                  N-[4-methyl-6-(1-oxobutylamino)-3-pyridinyl]-4-pyridinecarboxamide 0
                                                  N-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]-3-pyridinecarboxamide 0
                                                  N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
                                                  N-[5-[(3-methoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-3-thiazolidinyl]-4-pyridinecarboxamide 0
                                                  N-[6-(1-oxopentylamino)-3-pyridinyl]-3-pyridinecarboxamide 0
                                                  N-[6-[[cyclohexyl(oxo)methyl]amino]-3-pyridinyl]-2-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[3-methoxy-4-[2-(4-methylanilino)-2-oxoethoxy]phenyl]methylideneamino]-3-pyridinecarboxamide 0
                                                  N-[[5-(4-nitrophenyl)-2-furanyl]methylideneamino]-3-pyridinecarboxamide 0
                                                  N-\{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl\}pyridine-3-carboxamide 0
                                                  N-hydroxy-4-pyridinecarboxamide 0
                                                  N-methyl-4-pyridone-3-carboxamide + 0
                                                  N-methyl-6-pyridone-3-carboxamide + 1
                                                  N-methyl-N-[5-(3-pyridinyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
                                                  N-methylnicotinamide 2
                                                  N-ribosyl-4-pyridone-3-carboxamide 0
                                                  Nicoxamat 0
                                                  acetic acid 2-[[oxo(3-pyridinyl)methyl]amino]ethyl ester 0
                                                  boscalid + 0
                                                  caerulomycin I 0
                                                  caerulomycinamide 0
                                                  cyclobutrifluram 0
                                                  diflufenican 0
                                                  flonicamid 0
                                                  florylpicoxamid 0
                                                  hydroxymethylnicotinamide 0
                                                  isonicotinamide + 8
                                                  motesanib 0
                                                  nicorandil 18
                                                  nicotinamide + 140